GlassScriptPhysician profile
Sai K Avula
NPI 1467441741
$3,999.36
in general payments reported to CMS, 2019-2025
41 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $438 · 2021: $386 · 2022: $789 · 2023: $609 · 2024: $774 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $614.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $563.85 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $445.62 | 2019-2024 | Ubrelvy, Synthroid, Qulipta |
| Abbott Laboratories | $305.34 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Corcept Therapeutics | $214.96 | 2019-2025 | Korlym |
| Pfizer INC. | $201.95 | 2019-2025 | |
| Esperion Therapeutics, INC. | $199.86 | 2020-2021 | |
| Astellas Pharma US INC | $166.04 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $116.16 | 2022-2025 | |
| Lilly USA, LLC | $98.51 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $87.45 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $84.35 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $80.73 | 2022-2024 | Purified Cortrophin Gel |
| Xeris Pharmaceuticals, INC. | $73.48 | 2021-2024 | Gvoke Hypopen |
| Medtronic, INC. | $64.78 | 2025 | Symplicity G3, Minimed 780g |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sai Avula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.